PCR17 Work Productivity Assessment in Clinical Trials and Subsequent Economic Modeling in Multiple Sclerosis (MS) in Two Health Technology Assessment (HTA) Archetypes

Abstract

Productivity loss constitutes a substantial proportion of indirect costs in many health conditions. For chronic conditions, such as MS, productivity decrements and associated indirect costs may increase with disease progression; however, trajectories of symptom burden, absenteeism/presenteeism, and costs are not fully characterized. Several instruments are available to assess productivity in MS and can be used to capture societal costs for economic modelling and subsequent HTA. We explored the frequency and manner in which such measures are employed in clinical studies and models.